Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan Nipro To Buy Two-Thirds Of Device-Maker Goodman For $36 Million

This article was originally published in PharmAsia News

Executive Summary

Japan's Nipro said it plans to buy a two-thirds stake in Goodman Co. Ltd, maker of medical equipment such as catheters, for $36 million and make it a subsidiary.

Japan's Nipro said it plans to buy a two-thirds stake in Goodman Co. Ltd, maker of medical equipment such as catheters, for $36 million and make it a subsidiary. The remaining third of shares would remain in the hands of Itochu, which was excluded from the deal. Nipro said it intends to take advantage of its domestic and foreign sales networks to market Goodman products abroad as well as co-develop others with the Goodman unit. Goodman directors have agreed to the arrangement, which gives Nipro until March 8 to amass the 67% stake. (Click here for more - a subscription may be required)

"Nipro Announces Tender Offer For Goodman" - Nikkei (Japan) (1/25/2013)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC082513

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel